[1. Barrientos JC. Management of Chronic Lymphocytic Leukemia in the Elderly. Cancer Control 2015 Oct; 22(4 Suppl): 17-23.10.1177/107327481502204s04476359926618342]Search in Google Scholar
[2. Jain N, O’Brien S. Initial treatment of CLL: integrating biology and functional status. Blood 2015; 126(4): 463-70.10.1182/blood-2015-04-585067462444126065656]Search in Google Scholar
[3. Mozas P, Rivas-Delgado A, Baumann T, et al. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. Blood Cancer J. 2018; 8(1): 1-5.10.1038/s41408-017-0044-5580253329339727]Search in Google Scholar
[4. Oscier D, Dearden C, Eren E, Fegan C, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012; 59: 541-64.10.1111/bjh.1206723057493]Search in Google Scholar
[5. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(suppl_5): 78-84.10.1093/annonc/mdv30326314781]Search in Google Scholar
[6. Bond AD, Huang Y, Fisher LJ, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. J Clin Oncol. 2019; 37, (15): 7511-7511.]Search in Google Scholar
[7. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997. J ClinOncol. 2007; 25(7): 799-804.10.1200/JCO.2006.08.308917283363]Search in Google Scholar
[8. Raedler AL. Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Eighth Annual Payers’ Guide -Select Drug Profiles, Payers’ Guide March 2017, Vol 10.]Search in Google Scholar
[9. Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014 Jul; 39(7): 483-519.]Search in Google Scholar
[10. Brown JR. How I treat CLL patients with ibrutinib. Blood 2018; 131(4): 379-86.10.1182/blood-2017-08-76471229255067]Search in Google Scholar
[11. Puiggros A, Blanco G, Espinet B. Genetic Abnormalities in Chronic Lymphocytic Leukemia:Where We Are and Where We Go. Biomed Res Int. 2014.10.1155/2014/435983405468024967369]Search in Google Scholar
[12. Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA,et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 2018; 132(21): 2249-59.10.1182/blood-2018-06-860593625100930254130]Search in Google Scholar